PE20211140A1 - Metodos de inactivacion virica para la fabricacion continua de anticuerpos - Google Patents

Metodos de inactivacion virica para la fabricacion continua de anticuerpos

Info

Publication number
PE20211140A1
PE20211140A1 PE2021000699A PE2021000699A PE20211140A1 PE 20211140 A1 PE20211140 A1 PE 20211140A1 PE 2021000699 A PE2021000699 A PE 2021000699A PE 2021000699 A PE2021000699 A PE 2021000699A PE 20211140 A1 PE20211140 A1 PE 20211140A1
Authority
PE
Peru
Prior art keywords
methods
inactivation
viric
antibodies
continuous manufacture
Prior art date
Application number
PE2021000699A
Other languages
English (en)
Inventor
Janice Hsiu Mei Lee
Shengjiang Liu
June Zou
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of PE20211140A1 publication Critical patent/PE20211140A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/06—Inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16761—Methods of inactivation or attenuation
    • C12N2710/16763—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13061—Methods of inactivation or attenuation
    • C12N2740/13063—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Detergent Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta divulgacion se relaciona con los metodos a usar en los virus de inactivacion. Los metodos de inactivacion del virus son para uso en la fabricacion del proceso continuo de un agente biologico, tal como un anticuerpo e incluyen la separacion de un eluato a un tratamiento ortogonal de pH bajo y detergente de manera simultanea en donde el tiempo para la inactivacion virica se reduce. Ademas, el detergente se puede agregar al sistema de amortiguacion en el proceso de purificacion para lograr el mismo efecto. Se conserva el agente biologico en cada caso de tratamiento
PE2021000699A 2018-11-15 2019-11-14 Metodos de inactivacion virica para la fabricacion continua de anticuerpos PE20211140A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862767652P 2018-11-15 2018-11-15
PCT/US2019/061436 WO2020102505A1 (en) 2018-11-15 2019-11-14 Viral inactivation methods for continuous manufacturing of antibodies

Publications (1)

Publication Number Publication Date
PE20211140A1 true PE20211140A1 (es) 2021-06-25

Family

ID=69024584

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021000699A PE20211140A1 (es) 2018-11-15 2019-11-14 Metodos de inactivacion virica para la fabricacion continua de anticuerpos

Country Status (16)

Country Link
US (1) US20220002679A1 (es)
EP (1) EP3880806A1 (es)
JP (1) JP2022507369A (es)
KR (1) KR20210091709A (es)
CN (1) CN113015795A (es)
AR (1) AR117081A1 (es)
AU (1) AU2019380308A1 (es)
BR (1) BR112021006498A2 (es)
CA (1) CA3119629A1 (es)
IL (1) IL282944A (es)
MX (1) MX2021005685A (es)
PE (1) PE20211140A1 (es)
SG (1) SG11202103790WA (es)
TW (1) TW202039836A (es)
WO (1) WO2020102505A1 (es)
ZA (1) ZA202104083B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115873810B (zh) * 2022-12-26 2024-02-09 苏州良辰生物医药科技有限公司 一种鼠白血病病毒的纯化方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0674531A1 (de) * 1992-12-16 1995-10-04 IMMUNO Aktiengesellschaft Verfahren zur herstellung eines virussicheren biologischen präparates
IL136552A (en) * 2000-06-05 2005-05-17 Omrix Biopharmaceuticals Ltd Method for the inactivation of viruses by a solvent - detergent combination and by nanofiltration
US9428546B2 (en) * 2010-07-30 2016-08-30 Pfizer Inc. Tandem purification of proteins
WO2014004103A1 (en) * 2012-06-29 2014-01-03 Emd Millipore Corporation Methods for inactivating viruses during a protein purification process
JP6465800B2 (ja) 2012-08-06 2019-02-06 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． エンベロープウイルスを不活化するための方法および組成物
CA2930687C (en) 2013-11-15 2024-04-23 Genentech, Inc. Methods for viral inactivation using eco-friendly detergents
EP4234569A3 (en) * 2014-04-15 2023-10-18 Boehringer Ingelheim International GmbH Method and use for continuously inactivating a virus during manufacture of a biological product
WO2016207328A1 (en) * 2015-06-24 2016-12-29 Glycotope Gmbh PROCESS FOR THE PURIFICATION OF γ-CARBOXYLATED POLYPEPTIDES

Also Published As

Publication number Publication date
MX2021005685A (es) 2021-07-07
JP2022507369A (ja) 2022-01-18
CN113015795A (zh) 2021-06-22
AU2019380308A1 (en) 2021-05-13
ZA202104083B (en) 2023-01-25
EP3880806A1 (en) 2021-09-22
TW202039836A (zh) 2020-11-01
KR20210091709A (ko) 2021-07-22
BR112021006498A2 (pt) 2021-07-06
CA3119629A1 (en) 2020-05-22
WO2020102505A1 (en) 2020-05-22
IL282944A (en) 2021-06-30
SG11202103790WA (en) 2021-05-28
AR117081A1 (es) 2021-07-07
US20220002679A1 (en) 2022-01-06

Similar Documents

Publication Publication Date Title
BR112018008326A2 (pt) composições e métodos para o tratamento de câncer
DOP2017000186A (es) Agentes inductores de apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes
EA201791086A1 (ru) Человеческие антитела против гемагглютинина вируса гриппа
EA201991862A1 (ru) Композиции и способы, предназначенные для лечения гемоглобинопатий
CO2017007619A2 (es) Anticuerpos humanos contra glicoproteína del virus ébola
BR112017012859A2 (pt) fosforamidatos para o tratamento do vírus da hepatite b
CO6640274A2 (es) Agentes inductores de apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes
BR112016016916A8 (pt) uso de um anticorpo que se liga à calicreína plasmática ativa para tratamento de angiodema hereditário (hae)
UY33047A (es) Agentes inductores de apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes
EA201591786A1 (ru) Монотерапия gla для применения в лечении рака
MX368177B (es) Proceso continuo de múltiples etapas para purificar anticuerpos.
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
PL412787A1 (pl) Oparty na makrofagach celowany system dostarczania związków związanych z ferrytyną
EA201892225A1 (ru) АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ
BR112017026061A2 (pt) composto, uso de um composto, e, método de tratamento de uma infecção viral
EA201692358A1 (ru) Производные изоиндолина для применения в лечении вирусной инфекции
BR112016028888A2 (pt) compostos que compreendem o sistema 1,1',2,5'-tetra hidro espiro [indol-3,2'-pirrol]-2,5'-diona como inibidores de interação proteína-proteína p53-mdm2
BR112013024974A2 (pt) composto, composição farmacêutica, método para o tratamento de infecções virais, e, processo para preparar um composto
BR112017020374A2 (pt) compostos bicíclicos fundidos para o tratamento de doença
PE20211140A1 (es) Metodos de inactivacion virica para la fabricacion continua de anticuerpos
EA201892448A1 (ru) Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
EA200901064A1 (ru) Лекарственное средство для лечения гриппа у птиц
EA201991927A1 (ru) Новый иммуностимулирующий макролид
BR112018074231A2 (pt) compostos bicíclicos fundidos para o tratamento de doença
EA202091563A1 (ru) Человеческие антитела к гемагглютинину вируса гриппа